iTRAQ-based proteomics analysis reveals novel candidates for platinum resistance of epithelial ovarian cancer

Platinum-based chemotherapy is commonly used in the treatment of various cancers, including epithelial ovarian cancer (EOC). However, in EOC, chemotherapy failure is mainly caused by platinum resistance. In this present study, we aimed to identify novel biomarkers for predicting platinum chemosensitivity. Fresh specimens of 16 serous high-grade ovarian cancer (HGSC) cases were collected during cytoreductive surgery. Isobaric tags were used to identify differentially expressed proteins in platinum-resistant samples (n = 8) and platinum-sensitive samples (n = 8). Compared to platinum-sensitive samples, 741 significantly differentially expressed proteins were detected, of which 325 were upregulated and 416 were downregulated. To validate the isobaric tags for relative and absolute quantification (iTRAQ) method, western blotting was performed on two upregulated proteins, angiomotin-like protein 1 (AMOTL1) and Lumican. The results showed that platinum-resistant tumor samples expressed significantly higher levels of AMOTL1 and Lumican than platinum-sensitive tumor samples. Altogether, we identified candidate proteins related to platinum resistance in ovarian cancer. Both AMOTL1 and Lumican seem to be promising biomarkers that could distinguish between platinum-resistant and platinum-sensitive EOC.

Epithelial ovarian cancer; Platinum resistance; Angiomotin-like protein 1; Lumican; Isobaric tags for relative and absolute quantitation

[1] Wang X, Xu X, Jiang G, Zhang C, Liu L, Kang J, et al. Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene. Journal of Cellular and Molecular Medicine. 2020; 24: 11177–11187.

[2] Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2021; 19: 191–226.

[3] Coleridge SL, Bryant A, Kehoe S, Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews. 2021; 2: CD005343.

[4] van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocrine-Related Cancer. 2018; 25: R303–R318.

[5] Lee H, Kwon OB, Lee JE, Jeon YH, Lee DS, Min SH, et al. Repositioning trimebutine maleate as a cancer treatment targeting ovarian cancer stem cells. Cells. 2021; 10: 918.

[6] Zhu M, Wang J, Wuna Y, Wang Y, Li H. Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46: 644–652.

[7] Vianello C, Cocetta V, Catanzaro D, Dorn GW, De Milito A, Rizzolio F, et al. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. Cell Death & Disease. 2022; 13: 398.

[8] Dettmer K, Stevens AP, Fagerer SR, Kaspar H, Oefner PJ. Amino acid analysis in physiological samples by GC-MS with propyl chloroformate derivatization and iTRAQ-LC-MS/MS. Methods in Molecular Biology. 2019; 393: 173–190.

[9] Li Y, Guo T, Wang X, Ni W, Hu R, Cui Y, et al. ITRAQ-based quantitative proteomics reveals the proteome profiles of MDBK cells infected with bovine viral diarrhea virus. Virology Journal. 2021; 18: 119.

[10] Swiatly A, Horala A, Matysiak J, Hajduk J, Nowak-Markwitz E, Kokot ZJ. Understanding ovarian cancer: iTRAQ-based poteomics for biomarker discovery. International Journal of Molecular Sciences. 2018; 19: 2240.

[11] Xu S, Wang Y, Li Y, Zhang L, Wang C, Wu X. Comprehensive analysis of inhibitor of differentiation/DNA-binding gene family in lung cancer using bioinformatics methods. Bioscience Reports. 2020; 40: BSR20193075.

[12] Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, et al. MiR-200c sensitizes olaparib-resistant ovarian cancer cells by targeting Neuropilin 1. Journal of Experimental & Clinical Cancer Research. 2020; 39: 3.

[13] Zhou Y, Zhang J, Li H, Huang T, Wong CC, Wu F, et al. AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis. Oncogene. 2020; 39: 4375–4389.

[14] Lv M, Shen Y, Yang J, Li S, Wang B, Chen Z, et al. Angiomotin family members: oncogenes or tumor suppressors? International Journal of Biological Sciences. 2017; 13: 772–781.

[15] Drubin DG, Nelson WJ. Origins of cell polarity. Cell. 1996; 84: 335–344.

[16] Miyoshi J, Takai Y. Structural and functional associations of apical junctions with cytoskeleton. Biochim Biophys Acta. 2008; 1778: 670–691.

[17] Couderc C, Boin A, Fuhrmann L, Vincent-Salomon A, Mandati V, Kieffer Y, et al. AMOTL1 promotes breast cancer progression and is antagonized by Merlin. Neoplasia. 2016; 18: 10–24.

[18] Delgado ILS, Carmona B, Nolasco S, Santos D, Leitão A, Soares H. MOB: pivotal conserved proteins in cytokinesis, cell architecture and tissue homeostasis. Biology. 2020; 9: E413.

[19] Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. Journal of Biological Chemistry. 2011; 286: 7018–7026.

[20] Oka T, Schmitt AP, Sudol M. Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene. 2012; 31: 128–134.

[21] Chen X, Li X, Hu X, Jiang F, Shen Y, Xu R, et al. LUM expression and its prognostic significance in gastric cancer. Frontiers in Oncology. 2020; 10: 605.

[22] Di Paolo A, Bocci G. Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Current Oncology Reports. 2007; 9: 109–114.

[23] Croix BS, Kerbel RS. Cell adhesion and drug resistance in cancer. Current Opinion in Oncology. 1997; 9: 549–556.

[24] Brézillon S, Untereiner V, Mohamed HT, Ahallal E, Proult I, Nizet P, et al. Label-free infrared spectral histology of skin tissue part II: impact of a lumican-derived peptide on melanoma growth. Frontiers in Cell and Developmental Biology. 2020; 8: 377.

[25] Moseley R, Stewart JE, Stephens P, Waddington RJ, Thomas DW. Extracellular matrix metabolites as potential biomarkers of disease activity in wound fluid: lessons learned from other inflammatory diseases? British Journal of Dermatology. 2004; 150: 401–413.

[26] Neill T, Schaefer L, Iozzo RV. Decoding the matrix: instructive roles of proteoglycan receptors. Biochemistry. 2015; 54: 4583–4598.

[27] Hsiao KC, Chu PY, Chang GC, Liu KJ. Elevated expression of lumican in lung cancer cells promotes bone metastasis through an autocrine regulatory mechanism. Cancers. 2020; 12: 233.

[28] Seya T, Tanaka N, Shinji S, Yokoi K, Koizumi M, Teranishi N, et al. Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis. Oncology Reports. 2006; 16: 1225–1230.

[29] Klejewski A, Sterzyńska K, Wojtowicz K, Świerczewska M, Partyka M, Brązert M, et al. The significance of lumican expression in ovarian cancer drug-resistant cell lines. Oncotarget. 2017; 8: 74466–74478.